JP2015533168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533168A5 JP2015533168A5 JP2015536906A JP2015536906A JP2015533168A5 JP 2015533168 A5 JP2015533168 A5 JP 2015533168A5 JP 2015536906 A JP2015536906 A JP 2015536906A JP 2015536906 A JP2015536906 A JP 2015536906A JP 2015533168 A5 JP2015533168 A5 JP 2015533168A5
- Authority
- JP
- Japan
- Prior art keywords
- oxopiperazin
- tetrahydroisoquinoline
- tetrazol
- acryloyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 230000009424 thromboembolic effect Effects 0.000 claims 6
- 239000005711 Benzoic acid Substances 0.000 claims 5
- 235000010233 benzoic acid Nutrition 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- WLYWXDYDKXCXKT-UHFFFAOYSA-N 2-[3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1H-isoquinoline-1-carboxamide Chemical group ClC=1C(=C(C(=CC=1)N1N=NN=C1)C=CC(=O)N1C(C2=CC=CC(=C2CC1)N1C(CN(CC1)C)=O)C(=O)N)F WLYWXDYDKXCXKT-UHFFFAOYSA-N 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- -1 3- (3-chloro-2-fluoro-6- (1H-tetrazol-1-yl) phenyl) acryloyl Chemical group 0.000 claims 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010014513 Embolism arterial Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010063544 Renal embolism Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 239000002473 artificial blood Substances 0.000 claims 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712850P | 2012-10-12 | 2012-10-12 | |
| US61/712,850 | 2012-10-12 | ||
| PCT/US2013/064423 WO2014059203A1 (en) | 2012-10-12 | 2013-10-11 | Crystalline forms of a factor xia inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533168A JP2015533168A (ja) | 2015-11-19 |
| JP2015533168A5 true JP2015533168A5 (OSRAM) | 2016-07-07 |
| JP6154473B2 JP6154473B2 (ja) | 2017-06-28 |
Family
ID=49474724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536906A Expired - Fee Related JP6154473B2 (ja) | 2012-10-12 | 2013-10-11 | 第ＸＩａ因子阻害剤の結晶形 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9920034B2 (OSRAM) |
| EP (1) | EP2906551B1 (OSRAM) |
| JP (1) | JP6154473B2 (OSRAM) |
| KR (1) | KR102143257B1 (OSRAM) |
| CN (1) | CN104837833B (OSRAM) |
| AU (1) | AU2013329125B2 (OSRAM) |
| BR (1) | BR112015007937A2 (OSRAM) |
| CA (1) | CA2888100A1 (OSRAM) |
| CL (1) | CL2015000916A1 (OSRAM) |
| CO (1) | CO7350621A2 (OSRAM) |
| CY (1) | CY1120238T1 (OSRAM) |
| DK (1) | DK2906551T3 (OSRAM) |
| EA (1) | EA032092B1 (OSRAM) |
| ES (1) | ES2668318T3 (OSRAM) |
| HR (1) | HRP20180465T1 (OSRAM) |
| HU (1) | HUE038272T2 (OSRAM) |
| IL (1) | IL238089B (OSRAM) |
| LT (1) | LT2906551T (OSRAM) |
| MA (1) | MA38071B1 (OSRAM) |
| MX (1) | MX351848B (OSRAM) |
| MY (1) | MY173058A (OSRAM) |
| NO (1) | NO2819265T3 (OSRAM) |
| NZ (1) | NZ707990A (OSRAM) |
| PE (1) | PE20150639A1 (OSRAM) |
| PH (1) | PH12015500678A1 (OSRAM) |
| PL (1) | PL2906551T3 (OSRAM) |
| PT (1) | PT2906551T (OSRAM) |
| RS (1) | RS57039B1 (OSRAM) |
| SG (1) | SG11201502605PA (OSRAM) |
| SI (1) | SI2906551T1 (OSRAM) |
| SM (1) | SMT201800262T1 (OSRAM) |
| TR (1) | TR201807316T4 (OSRAM) |
| WO (1) | WO2014059203A1 (OSRAM) |
| ZA (1) | ZA201503238B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| PH12014500625B1 (en) | 2011-10-14 | 2018-12-12 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| SG10201908467RA (en) | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| NO2760821T3 (OSRAM) | 2014-01-31 | 2018-03-10 | ||
| WO2016036893A1 (en) | 2014-09-04 | 2016-03-10 | Bristol-Myers Squibb Company | Diamide macrocycles that are fxia inhibitors |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| US10160750B2 (en) | 2015-06-19 | 2018-12-25 | Bristol-Myers Squibb Company | Diamide macrocycles as factor XIa inhibitors |
| CN107849026B (zh) | 2015-07-29 | 2021-01-01 | 百时美施贵宝公司 | 携带烷基或环烷基p2′部分的因子xia大环抑制剂 |
| KR102729666B1 (ko) | 2015-07-29 | 2024-11-12 | 브리스톨-마이어스 스큅 컴퍼니 | 비-방향족 P2' 기를 갖는 인자 XIa 신규 마크로사이클 |
| CN106496249B (zh) * | 2015-09-07 | 2019-12-13 | 江苏恒瑞医药股份有限公司 | 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用 |
| EP3371162B1 (en) | 2015-10-29 | 2022-01-26 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
| WO2018039094A1 (en) | 2016-08-22 | 2018-03-01 | Merck Sharp & Dohme Corp. | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| CN109867660A (zh) * | 2017-12-01 | 2019-06-11 | 四川科伦博泰生物医药股份有限公司 | 含季铵离子的四氢异喹啉酰胺化合物及其药物用途 |
| EP3778597B1 (en) | 2018-03-28 | 2025-05-28 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Tetrahydroisoquinoline derivative, preparation method therefor and uses thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR7155E (fr) | 1906-03-16 | 1907-05-23 | Rene Gabriel Poncet | Séchoir rotatif |
| FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
| ATA937274A (de) | 1973-12-17 | 1978-02-15 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer araliphatischer ketone |
| DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
| JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| WO1996034010A2 (en) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0891352A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| TR200103406T2 (tr) | 1998-03-19 | 2002-06-21 | Vertex Pharmaceuticals Incorporated | Kaspaz inhibitörleri. |
| SK17532000A3 (sk) | 1998-05-26 | 2002-08-06 | Warner-Lambert Company | Prípadne substituované 3,4-dihydrogenované pyrimidíny, ich použitie a farmaceutické formulácie na ich báze |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| CA2358578A1 (en) | 1999-01-02 | 2000-07-13 | Aventis Pharma Deutschland Gmbh | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) |
| EP1016663A1 (en) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
| HK1045846A1 (zh) | 1999-04-09 | 2002-12-13 | 巴斯福股份公司 | 低分子量补体蛋白酶抑制剂 |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| ATE310728T1 (de) | 2000-05-11 | 2005-12-15 | Bristol Myers Squibb Co | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| WO2003011222A2 (en) | 2001-07-27 | 2003-02-13 | Merck & Co., Inc. | Thrombin inhibitors |
| US6649606B1 (en) | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| EP2457895A1 (en) | 2004-07-12 | 2012-05-30 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
| EP1841504B1 (en) | 2005-01-13 | 2014-11-19 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor xia inhibitors |
| WO2006089005A2 (en) | 2005-02-17 | 2006-08-24 | Bristol-Myers Squibb Company | Combination of selective factor viia and/or xia and plasma kallikrein inhibitors |
| CA2627426A1 (en) * | 2005-11-11 | 2007-05-18 | Markus Boehringer | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa |
| JP2009519966A (ja) | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な６員ヘテロ環 |
| WO2007070816A2 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Thiophene derivatives as factor xia inhibitors |
| EA014245B1 (ru) | 2005-12-14 | 2010-10-29 | Бристол-Маерс Сквибб Компани | Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia |
| AR058380A1 (es) | 2005-12-23 | 2008-01-30 | Bristol Myers Squibb Co | Inhibidores del factor viia macrociclicos utiles como anticoagulantes |
| ES2546815T3 (es) | 2006-12-15 | 2015-09-28 | Bristol-Myers Squibb Company | Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa |
| PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| PE20091002A1 (es) | 2007-06-13 | 2009-07-15 | Bristol Myers Squibb Co | Analogos dipeptidos como inhibidores del factor de coagulacion |
| WO2009114677A1 (en) * | 2008-03-13 | 2009-09-17 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| WO2010151317A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2011002520A2 (en) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
| AR077695A1 (es) | 2009-08-04 | 2011-09-14 | Schering Corp | Derivados de pirimidina como inhibidores del factor ixa |
| WO2011100401A1 (en) | 2010-02-11 | 2011-08-18 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
| US9161924B2 (en) | 2011-07-08 | 2015-10-20 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| CN103987696B (zh) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
| PH12014500625B1 (en) * | 2011-10-14 | 2018-12-12 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| CN103987697B (zh) | 2011-10-14 | 2017-04-26 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
| IN2014CN04676A (OSRAM) | 2011-12-21 | 2015-09-18 | Ono Pharmaceutical Co | |
| WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| CA2872926C (en) | 2012-05-10 | 2022-07-05 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
| US9758480B2 (en) | 2012-07-19 | 2017-09-12 | Sumitomo Dainippon Pharma Co., Ltd. | 1-(cycloalkyl-carbonyl)proline derivative |
| HRP20161378T1 (hr) | 2012-08-03 | 2016-12-02 | Bristol-Myers Squibb Company | Dihidropiridon kao faktor xia inhibitora |
| HUE032622T2 (en) | 2012-08-03 | 2017-10-30 | Bristol Myers Squibb Co | Dihydropyridone p1 as factor xia inhibitors |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| US9708308B2 (en) | 2012-12-19 | 2017-07-18 | Merck Sharp Dohme Corp. | Factor IXa inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
-
2013
- 2013-10-11 MX MX2015004328A patent/MX351848B/es active IP Right Grant
- 2013-10-11 HR HRP20180465TT patent/HRP20180465T1/hr unknown
- 2013-10-11 CA CA2888100A patent/CA2888100A1/en not_active Abandoned
- 2013-10-11 SG SG11201502605PA patent/SG11201502605PA/en unknown
- 2013-10-11 PE PE2015000477A patent/PE20150639A1/es not_active Application Discontinuation
- 2013-10-11 AU AU2013329125A patent/AU2013329125B2/en not_active Ceased
- 2013-10-11 CN CN201380064797.5A patent/CN104837833B/zh not_active Expired - Fee Related
- 2013-10-11 EA EA201590548A patent/EA032092B1/ru not_active IP Right Cessation
- 2013-10-11 ES ES13780287.2T patent/ES2668318T3/es active Active
- 2013-10-11 SI SI201330987T patent/SI2906551T1/en unknown
- 2013-10-11 US US14/434,507 patent/US9920034B2/en active Active
- 2013-10-11 EP EP13780287.2A patent/EP2906551B1/en active Active
- 2013-10-11 LT LTEP13780287.2T patent/LT2906551T/lt unknown
- 2013-10-11 DK DK13780287.2T patent/DK2906551T3/en active
- 2013-10-11 PT PT137802872T patent/PT2906551T/pt unknown
- 2013-10-11 WO PCT/US2013/064423 patent/WO2014059203A1/en not_active Ceased
- 2013-10-11 JP JP2015536906A patent/JP6154473B2/ja not_active Expired - Fee Related
- 2013-10-11 RS RS20180328A patent/RS57039B1/sr unknown
- 2013-10-11 HU HUE13780287A patent/HUE038272T2/hu unknown
- 2013-10-11 TR TR2018/07316T patent/TR201807316T4/tr unknown
- 2013-10-11 MY MYPI2015701150A patent/MY173058A/en unknown
- 2013-10-11 BR BR112015007937A patent/BR112015007937A2/pt not_active Application Discontinuation
- 2013-10-11 KR KR1020157011941A patent/KR102143257B1/ko not_active Expired - Fee Related
- 2013-10-11 SM SM20180262T patent/SMT201800262T1/it unknown
- 2013-10-11 PL PL13780287T patent/PL2906551T3/pl unknown
- 2013-10-11 NZ NZ707990A patent/NZ707990A/en not_active IP Right Cessation
-
2014
- 2014-05-21 NO NO14169333A patent/NO2819265T3/no unknown
-
2015
- 2015-03-26 PH PH12015500678A patent/PH12015500678A1/en unknown
- 2015-04-01 IL IL238089A patent/IL238089B/en active IP Right Grant
- 2015-04-10 CL CL2015000916A patent/CL2015000916A1/es unknown
- 2015-05-07 MA MA38071A patent/MA38071B1/fr unknown
- 2015-05-07 CO CO15104857A patent/CO7350621A2/es unknown
- 2015-05-11 ZA ZA2015/03238A patent/ZA201503238B/en unknown
-
2018
- 2018-05-18 CY CY20181100522T patent/CY1120238T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533168A5 (OSRAM) | ||
| HRP20180465T1 (hr) | Kristalni oblici inhibitora faktora xia | |
| RU2013125480A (ru) | Стимуляторы sgc | |
| JP2012532112A5 (OSRAM) | ||
| JP2015522616A5 (OSRAM) | ||
| JP2011520967A5 (OSRAM) | ||
| JP2024050527A5 (OSRAM) | ||
| HRP20140714T1 (hr) | Alkilamin-supstituirani dicijanopiridin i njegovi esterski amino kiselinski predlijekovi | |
| JP2015524443A5 (OSRAM) | ||
| JP2019034943A5 (OSRAM) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| JP2019094345A5 (OSRAM) | ||
| JP2014097964A5 (OSRAM) | ||
| HRP20161378T1 (hr) | Dihidropiridon kao faktor xia inhibitora | |
| JP2018501285A5 (OSRAM) | ||
| JP2018509451A5 (OSRAM) | ||
| JP2010510999A5 (OSRAM) | ||
| JP2011527994A5 (OSRAM) | ||
| JP2019527215A5 (OSRAM) | ||
| JP2012502890A5 (OSRAM) | ||
| JP2016540051A5 (OSRAM) | ||
| JP2019131544A5 (OSRAM) | ||
| CA2578596C (en) | Substituted phenylaminothiazoles and their use | |
| JP2018525371A5 (OSRAM) | ||
| JP2005529842A5 (OSRAM) |